Months af­ter steer­ing a seizure res­cue ther­a­py to mar­ket, UCB bags an­oth­er promis­ing late-stage as­set for $125M ...

5 years ago
Deals

Covid-19 roundup: Yet more dos­es of the As­traZeneca-Ox­ford vac­cine; A sec­ond ran­dom­ized hy­drox­y­chloro­quine study ...

5 years ago
Coronavirus

Add ear gene ther­a­py com­pa­ny Ak­ou­os to the ever-grow­ing list of IPOs amid Covid-19

5 years ago
Financing
Startups

Does As­traZeneca CEO Pas­cal So­ri­ot re­al­ly want to merge with Gilead? A Bloomberg sto­ry sug­gests he was in­ter­est­ed — ...

5 years ago
Deals

Al­ny­lam sets up 3rd po­ten­tial RNAi ap­proval with a show­case of pos­i­tive lumasir­an da­ta

5 years ago
R&D

Leg­end fetch­es $424 mil­lion, emerges as biggest win­ner yet in pan­dem­ic IPO boom as shares soar

5 years ago
Financing
R&D

Mer­ck wins a third FDA nod for an­tibi­ot­ic; Mereo tack­les TIG­IT with $70M raise in hand

5 years ago
News Briefing

As it hap­pened: A bid­ding war for an an­tibi­ot­ic mak­er in a mar­ket that has rav­aged its peers

5 years ago
R&D

RA Cap­i­tal, Hill­house join $310M rush to back Ever­est's climb to com­mer­cial heights in Chi­na

5 years ago
Financing
China

David Chang steps up to CEO spot at WuX­i's cell and gene ther­a­py CD­MO; David Meline is the new CFO at Mod­er­na

5 years ago
Peer Review

Mod­er­na’s new CFO took a cut in salary to jump to the mR­NA rev­o­lu­tion­ary. But then there’s the rest of the ...

5 years ago
People

Por­tion of Neil Wood­ford’s re­main­ing in­vest­ments, in­clud­ing Nanopore, sold off for $284 mil­lion

5 years ago
Financing
Deals

Drug man­u­fac­tur­ing gi­ant Lon­za taps Roche/phar­ma ‘rein­ven­tion’ vet as its new CEO

5 years ago
People
Outsourcing

Covid-19 roundup: Ab­b­Vie jumps in­to Covid-19 an­ti­body hunt; As­traZeneca shoots for 2B dos­es of Ox­ford vac­cine — ...

5 years ago
Coronavirus

At­las rais­es new $400M fund amid spree of VC rais­es. Here’s what they’ll spend it on

5 years ago
Financing

Caught in a stand­off with its con­tract man­u­fac­tur­er over Covid-19 vac­cine, In­ovio files suit in an at­tempt to break ...

5 years ago
Coronavirus

Bris­tol My­ers is clean­ing up the post-Cel­gene merg­er pipeline, and they’re sweep­ing out an ex­per­i­men­tal check­point ...

5 years ago
Deals

Gilead bol­sters its case for block­buster hope­ful fil­go­tinib as FDA pon­ders its de­ci­sion

5 years ago
R&D

Glax­o­SmithK­line cell ther­a­py lead leaves for part­ner; Fer­ring and Igenomix cre­ate Boston hub for ma­ter­nal health

5 years ago
News Briefing

Am­gen vet David Meline finds a new CFO roost at Mod­er­na, tak­ing a ride on the Covid-19 tiger as de­part­ing ex­ec cash­es ...

5 years ago
People

Can a small biotech suc­cess­ful­ly tack­le an Ever­est climb like Alzheimer’s? Athi­ra has $85M and some in­flu­en­tial ...

5 years ago
Financing
R&D

GSK presents case to ex­pand use of its lu­pus drug in pa­tients with kid­ney dis­ease, but the field is evolv­ing. How ...

5 years ago
R&D
Pharma

Covid-19 roundup: Mod­er­na read­ies to en­ter PhI­II in Ju­ly, As­traZeneca not far be­hind; EU ready to ne­go­ti­ate vac­cine ...

5 years ago
Coronavirus

New safe­ty da­ta ex­pose po­ten­tial weak­ness as Pfiz­er's abroc­i­tinib takes on Dupix­ent in eczema

5 years ago
R&D
First page Previous page 820821822823824825826 Next page Last page
A service from the Financial Times